NovAliX enters into fragment-based drug discovery alliance with Kyowa Hakko Kirin.

January 14, 2013 - Events
 class='attachment-visuel-actu wp-post-image'

Novalix enters into fragment-based drug discovery alliance with Kyowa Hakko Kirin

Strasbourg, France, January 14, 2013/ b3c newswire

NovAliX SAS announced today that it has entered into a fragment-based drug discovery alliance with Kyowa Hakko Kirin Co., Ltd., Japan.

Within the alliance, the companies will collaborate to develop novel drug candidates against protein-protein interaction targets. NovAliX will generate novel lead candidates using the broad spectrum of its biophysical capabilities and its medicinal chemistry expertise.

Under the terms of the agreement NovAliX will receive technology access fees as well as further research funding payments and milestones.

Stephan Jenn, President of NovAliX, stated, ” For NovAliX this drug discovery alliance represents a significant development of our established relation with Kyowa Hakko Kirin. This drug discovery collaboration with a leading Japanese pharmaceutical company also confirms the quality of our discovery platforms and its ability to deliver valuable lead candidates.

About NovAliX

NovAliX is providing enabling chemistry and biophysical technologies to support the pharmaceutical industry’s outsourcing needs from discovery to manufacturing. With its proprietary Graffinity SPR technology, X-ray protein crystallography, native mass spectrometry and chemistry NovAliX offers comprehensive integrated services for small molecule drug discovery. With advanced NMR technologies, NovAliX provides fine characterization of biologics, thorough analysis of APIs and polymorphism studies to support pharmaceutical development and manufacturing teams. NovAliX Group, a team of 130 scientists, is located in Strasbourg-Illkirch (France) and Heidelberg (NovAliX’s Graffinity subsidiary in Germany). More info at: www.novalix-pharma.com.

About Kyowa Hakko Kirin

Kyowa Hakko Kirin is a leading biopharmaceutical company in Japan focusing on its core business
area of oncology, nephrology and immunology/allergy. Kyowa Hakko Kirin leverages antibody-related
leading-edge technologies to discover and develop innovative new drugs aiming to become a global
specialty pharmaceutical company which contributes to the health and well-being of people around the
world. For more information, visit http://www.kyowa-kirin.com.

Contact:

Denis Zeyer, CEO
NovAliX
Bld Sébastien Brant, BP 30170
F-67405 Illkirch CEDEX FRANCE
Phone : +33 368 330 200
info@novalix-pharma.com

Link to the PDF file